Zhan Qu

Dr. Zhan Qu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
ZQZhan Qu
Zhan Qu
MPMonica Parry
Monica Parry
FLFang Liu
Fang Liu
XWXiulin Wen
Xiulin Wen
JLJieqiong Li
Jieqiong Li
XLXiaomei Li
Xiaomei Li
Objectives This study explored the relationship between self-management and blood pressure (BP) control in China. Design A cross-sectional study. Setting Eight community health centres from four cities in the Northeast (Shenyang), Northwest (Xi’an), Southwest (Chengdu) and South (Changsha) of China. Participants A total of 873 adults with hypertension, including 360 men and 513 women. Hypertension was defined as systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg. Outcome measurements BP control was the primary outcome variable. This was categorised as good control if individuals with hypertension reduced their BP to <140/90 mm Hg, otherwise, it was categorised as poor control. Secondary outcomes included self-management, defined as: (1) context or condition-specific factors or physical/social environments (eg, age, sex, marital status, education, personal income and health insurance) and (2) process or knowledge/beliefs, self-regulation skills/abilities and social facilitation (eg, treatment, diet, exercise and risk factor management). Data were analysed using logistic regression models using SPSS V.20. Results A total of 67.1% (n=586) participants had poor BP control. Limited outpatient care benefits in mainly rural residents (OR 2.26, 95% CI 1.06 to 4.81) and longer disease duration (OR 1.03, 95% CI 1.01 to 1.04) were associated with poor BP control. Self-management practices reduced the odds of having poor BP control (OR 0.98, 95% CI 0.97 to 0.99). Conclusions The individual and family self-management theory can serve as an effective theory for understanding the key contexts, processes and outcomes essential for BP control in China. Future research should evaluate the effect of a self-management intervention (eg, self-monitoring, medication adherence, regular and routine doctor visits, and social supports) for BP control in China using a multisite cluster randomised controlled trial. Sex and gender difference, cost and patient-reported outcomes should also be examined.

23 September 2024 in Medcomm
Verified
Journal Article
Open access
SLShuge Liu
Shuge Liu
YCYating Chen
Yating Chen
ZWZhiyao Wang
Zhiyao Wang
MLMinggao Liu
Minggao Liu
YZYundi Zhao
Yundi Zhao
CWChunsheng Wu
Chunsheng Wu
Bioprinting is a highly promising application area of additive manufacturing technology that has been widely used in various fields, including tissue engineering, drug screening, organ regeneration, and biosensing. Its primary goal is to produce biomedical products such as artificial implant scaffolds, tissues and organs, and medical assistive devices through software‐layered discrete and numerical control molding. Despite its immense potential, bioprinting technology still faces several challenges. It requires concerted efforts from researchers, engineers, regulatory bodies, and industry stakeholders are principal to overcome these challenges and unlock the full potential of bioprinting. This review systematically discusses bioprinting principles, applications, and future perspectives while also providing a topical overview of research progress in bioprinting over the past two decades. The most recent advancements in bioprinting are comprehensively reviewed here. First, printing techniques and methods are summarized along with advancements related to bioinks and supporting structures. Second, interesting and representative cases regarding the applications of bioprinting in tissue engineering, drug screening, organ regeneration, and biosensing are introduced in detail. Finally, the remaining challenges and suggestions for future directions of bioprinting technology are proposed and discussed.Bioprinting is one of the most promising application areas of additive manufacturing technology that has been widely used in various fields. It aims to produce biomedical products such as artificial implant scaffolds, tissues and organs, and medical assistive devices. This review systematically discusses bioprinting principles, applications, and future perspectives, which provides a topical description of the research progress of bioprinting.

22 August 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
YCYuqi Chen
Yuqi Chen
SLShuge Liu
Shuge Liu
YCYating Chen
Yating Chen
MWmiaomiao wang
miaomiao wang
YLYage Liu
Yage Liu
CWChunsheng Wu
Chunsheng Wu
The integration of organoids with biosensors serves as a miniaturized model of human physiology and diseases, significantly transforming the research frameworks surrounding drug development, toxicity testing, and personalized medicine. This review aims to provide a comprehensive framework for researchers to identify suitable technical approaches and to promote the advancement of organoid sensing towards enhanced biomimicry and intelligence. To this end, several primary methods for technology integration are systematically outlined and compared, which include microfluidic integrated systems, microelectrode array (MEA)-based electrophysiological recording systems, optical sensing systems, mechanical force sensing technologies, field-effect transistor (FET)-based sensing techniques, biohybrid systems based on synthetic biology tools, and label-free technologies, including impedance, surface plasmon resonance (SPR), and mass spectrometry imaging. Through multimodal collaboration such as the combination of MEA for recording electrical signals from cardiac organoids with micropillar arrays for monitoring contractile force, these technologies can overcome the limitations inherent in singular sensing modalities and enable a comprehensive analysis of the dynamic responses of organoids. Furthermore, this review discusses strategies for integrating strategies of multimodal sensing approaches (e.g., the combination of microfluidics with MEA and optical methods) and highlights future challenges related to sensor implantation in vascularized organoids, signal stability during long-term culture, and the standardization of clinical translation.

1 March 2022 in Arabian Journal of Chemistry
Verified
Journal Article
Open access
RBRui Bian
Rui Bian
TSTing Su
Ting Su
YGYidi Gao
Yidi Gao
YCYu Chen
Yu Chen
SZSuiyi Zhu
Suiyi Zhu
HZHong Zhang
Hong Zhang

8 February 2024 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
YCYating Chen
Yating Chen
YLYiwei Liu
Yiwei Liu
PZPing Zhu
Ping Zhu
SLShuge Liu
Shuge Liu
MWMiaomiao Wang
Miaomiao Wang
CWChunsheng Wu
Chunsheng Wu
An electrochemical biosensor was developed for OA detection using a reverse amplification function based on C3N4-aptamer-Th and C3N4-ssDNA.

2 October 2024 in Chemosensors
Verified
Journal Article
Open access
PDF file
JLJunrong Li
Junrong Li
DDDing Ding
Ding Ding
石宇石 宇萱
石 宇萱
ZLZhiying Liu
Zhiying Liu
JLJun Lin
Jun Lin
CWChunsheng Wu
Chunsheng Wu
Biosensors have emerged as a promising tool for the early detection of oral squamous cell carcinoma (OSCC) due to their rapid, sensitive, and specific detection of cancer biomarkers. Saliva is a non-invasive and easy-to-obtain biofluid that contains various biomarkers of OSCC, including the carcinoembryonic antigen (CEA). In this study, an electrochemical aptasensor for the detection of CEA in saliva has been developed towards the diagnosis and early screening of OSCC. This aptasensor utilized a CEA-sensitive aptamer as sensitive elements. A fluorine-doped Tin Oxide (FTO) chip with a surface modification of a zinc oxide nanorod was employed as a transducer. Electrochemical measurements were carried out to detect the responsive signals originating from the specific binding between aptamers and CEAs. The measurement results indicated that this aptasensor was responsive to different concentrations of CEA ranging from 1 ng/mL to 80 ng/mL in a linear relationship. The limit of detection (LOD) was 0.75 ng/mL. This aptasensor also showed very good specificity and regenerative capability. Stability testing over a 12-day period showed excellent performance of this aptasensor. All the results demonstrated that this aptasensor has great potential to be used for the detection of CEA in the saliva of OSCC patients. This aptasensor provides a promising method for the rapid detection of CEA with convenience, which has great potential to be used as a new method for clinical diagnoses and early screening of OSCC.